Sysmex (OTCMKTS:SSMXY) Reaches New 52-Week Low – Time to Sell?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $8.01 and last traded at $8.2348, with a volume of 309220 shares. The stock had previously closed at $8.53.

Analyst Ratings Changes

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold”.

Sysmex Stock Down 0.4%

The business’s 50 day moving average is $8.73 and its 200 day moving average is $9.11. The company has a market capitalization of $5.35 billion, a price-to-earnings ratio of 22.37 and a beta of 1.10. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $877.92 million for the quarter, compared to analyst estimates of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Sell-side analysts anticipate that Sysmex Corporation ADR will post 0.37 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.